iwCLL 2017 | How can we overcome ibrutinib resistance?

Meixiao Long

Meixiao Long, MD from the Ohio State University, Columbus, OH discusses leukemia cell resistance to ibrutinib. He believes in a multimodal combination approach with immunotherapy to bypass ibrutinib resistance, for e.g. tumour vaccines or checkpoint blockade, which can hopefully lead to durable response rates. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY.

Share this video